What KPV is

KPV belongs to the immunomodulatory-peptide family — a group of compounds developed from research on thymic peptides and short anti-inflammatory sequences. Unlike broad immunosuppressants or immune-stimulators, this class exerts targeted, receptor-mediated modulation of specific immune subsets.

• Thymosin Alpha-1 (Tα1, Zadaxin) is a 28-amino-acid peptide originally isolated from thymus tissue. It is approved for clinical use in over 35 countries (not the U.S.) as an adjunct in chronic hepatitis B and C and in immunocompromised patient protocols.
• KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val). Despite its short sequence, it retains substantial anti-inflammatory activity — particularly at intestinal and dermal sites — without α-MSH's pigmentary effect.

Mechanism of action

• Thymosin Alpha-1 — activates TLR2 and TLR9 pathways on plasmacytoid dendritic cells and CD4⁺ T-cells, restoring Th1 cytokine profile in immunocompromised populations. It enhances antigen-specific T-cell response without generalized inflammation.
• KPV — acts on melanocortin-1 receptor (MC1R) and downregulates NF-κB signaling in enterocytes, macrophages, and mast cells. Its anti-inflammatory activity in colitis models is one of the most consistent findings in the α-MSH-fragment literature.

Published research findings

• Thymosin Alpha-1 has published data in HBV/HCV combination therapy, sepsis-adjunct protocols, immunosenescence, and (during 2020-2021) as an off-label adjunct in severe COVID pneumonia (multiple Chinese and Italian case series).
• KPV has published data in DSS-colitis models, atopic-dermatitis models, and oral-inflammation research.

Dosing ranges reported in the literature

• Thymosin Alpha-1: 1.6 mg subcutaneous, dosed twice weekly in HBV/HCV protocols; some immunosenescence protocols dose daily for a loading period.
• KPV: 250–500 µg subcutaneous or oral (with acid protection) daily in research protocols; topical formulations for dermatological research.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing KPV for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for KPV, cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for KPV

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

KPV is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards